Central California Blood Center starts experimental treatment to fight COVID-19

The Central California Blood Center announced that they will be the first blood center in the United States to produce pathogen-reduced plasma from patients who have successfully recovered from the Coronavirus. The Blood Center said people who recover from the Coronavirus infection have developed antibodies to the virus that remain in the plasma portion of their blood. The experimental treatment is approved by the U.S. Food and Drug Administration (FDA) to be used on an emergency basis.